Riskpilot← Back to searchSign inGet full accessHECO LABORATORIEUTSTYR AS
ASActiveOrg 936711707Lilleakerveien 31, 0283 OsloWholesale of pharmaceutical and medical goods · NACE 4646Est. 198515 employeeswww.heco.no
Revenue 2024
NOK 47,1M
+15% vs 2023
EBITDA margin
4.4%
+153% vs 2023
Equity ratio
5.8%
Financial strength
Net profit 2024
NOK 246K
+105% vs 2023
| Revenue | NOK 47,1M | +15% |
| EBITDA | NOK 2,1M | +153% |
| Net profit | NOK 246K | +105% |
| Total assets | NOK 24,6M | +35% |
| Equity | NOK 1,4M | +21% |
| Employees | 15 | — |
Legal name
HECO LABORATORIEUTSTYR AS
Org number
936711707
Legal form
Aksjeselskap
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
15. februar 1985
Share capital
—
Employees
15 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Address
Lilleakerveien 31, 0283 Oslo
Website
www.heco.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 34 786 | 35 986 | 36 647 | 41 017 | 47 100 |
| Staff expenses | −10 550 | −11 769 | −11 709 | −11 440 | −8 068 |
| EBITDA | −1 913 | −364 | −2 055 | −3 850 | 2 056 |
| Depreciation & amort. | −23 | −43 | −165 | −501 | −512 |
| EBIT | −1 936 | −406 | −2 220 | −4 351 | 1 544 |
| Net financials | −235 | 562 | 295 | −152 | −1 298 |
| Profit before tax | −2 171 | 155 | −1 925 | −4 503 | 246 |
| Tax | −414 | −0 | −0 | −0 | −0 |
| Net profit | −1 757 | 155 | −1 925 | −4 503 | 246 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 20 568 | 19 234 | 19 723 | 18 231 | 24 616 |
| Equity | 7 461 | 7 616 | 5 691 | 1 189 | 1 435 |
| Long-term debt | 1 890 | 1 710 | 1 530 | 1 350 | 7 651 |
| Short-term debt | 11 217 | 9 908 | 12 502 | 15 692 | 15 530 |
| Total debt | 13 107 | 11 618 | 14 032 | 17 042 | 23 181 |
EBITDA margin
4.4%
This company
15.8%
Market median
-72% vs market
20202024
Equity ratio
5.8%
This company
38.2%
Market median
-85% vs market
20202024
Return on equity
17.2%
This company
18.4%
Market median
+7% vs market
20202024
Net profit margin
0.5%
This company
8.1%
Market median
-94% vs market
20202024
Asset turnover
1.91×
This company
1.12×
Market median
+71% vs market
20202024
Debt / equity
16.16×
This company
0.62×
Market median
-2506% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
LM Chief Executive Officer | Chief Executive Officer | 2018 |
CH Deputy Member | Deputy Member | 2023 |
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Board of Directors | 2023 | |
| Board of Directors | 2023 | |
| Chairman | 2023 | |
| Board of Directors | 2023 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
HECO LABORATORIEUTSTYR AS 
INTERNOVA AVIATION - MARINE - SURFACE ASBoard members of HECO LABORATORIEUTSTYR AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lars Magnus Mikkelsen | Chief Executive Officer | 0 companies |
| Christopher Hellebust | Deputy Member | 0 companies |
| Espen Thømming | Board of Directors | 0 companies |
| Karl Magnus Von Krogh | Board of Directors | 0 companies |
| Solveig Lilholt | Chairman | 0 companies |
| Severin Jan Hellebust | Board of Directors | 0 companies |